KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
Form 4 KalVista Pharmaceuticals For: Dec 06 Filed by: Palleiko Benjamin L
Form 4 KalVista Pharmaceuticals For: Nov 21 Filed by: Sweeny Nicole
Form 4 KalVista Pharmaceuticals For: Nov 21 Filed by: Piekos Brian
Form 4 KalVista Pharmaceuticals For: Nov 21 Filed by: Yea Christopher
Form 4 KalVista Pharmaceuticals For: Nov 21 Filed by: Audhya Paul K.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.